Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Biochemical Pharmacology

Volumn 88, Issue 4, 2014, Pages 426-449

  Hampel, Harald ^a   Lista, Simone ^b   Teipel, Stefan J ^c,d   Garaci, Francesco ^e,f   Nisticò, Robert ^g,h   Blennow, Kaj ⁱ   Zetterberg, Henrik ^i,j   Bertram, Lars ^k   Duyckaerts, Charles ^l   Bakardjian, Hovagim ^l,m   Drzezga, Alexander ⁿ   Colliot, Olivier ^a,o,p,q,r   Epelbaum, Stéphane ^a,l   Broich, Karl ^s   Lehéricy, Stéphane ^a,l,o,p,q   Brice, Alexis ^a,l,o,p,q   Khachaturian, Zaven S ^t   Aisen, Paul S ^u   Dubois, Bruno ^a,l  

^a SORBONNE UNIVERSITÉ   (France)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f IRCCS SAN RAFFAELE PISANA   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h IRCCS FONDAZIONE SANTA LUCIA   (Italy)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

^k MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^l PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^m Institute for Memory and Alzheimer's Disease   (France)

ⁿ UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^o INSERM   (France)

^p CNRS   (France)

^q INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^r INRIA ROCQUENCOURT   (France)

^s Federal Institute for Drugs and Medical Devices BfArM   (Germany)

^t Campaign to Prevent Alzheimer's Disease by 2020 (PAD2020)   (United States)

^u UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Alzheimer's disease; Clinical trials; CSF blood biomarkers; PET imaging markers; Structural functional MRI markers

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; GAMMA SECRETASE; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ALZHEIMER DISEASE; BASIC RESEARCH; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFUSION TENSOR IMAGING; ELECTROENCEPHALOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INTERVENTION STUDY; MOLECULAR MECHANICS; NATIONAL HEALTH ORGANIZATION; NERVE CELL DEGENERATION; NEUROIMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTING STATE NETWORK; REVIEW; SENSITIVITY AND SPECIFICITY;

ALZHEIMER'S DISEASE; CLINICAL TRIALS; CSF/BLOOD BIOMARKERS; PET IMAGING MARKERS; STRUCTURAL/FUNCTIONAL MRI MARKERS;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 84897954102     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.11.009     Document Type: Review

References (327)

1. H. Braak, and E. Braak Neuropathological staging of Alzheimer-related changes Acta Neuropathol 82 1991 239 259
2. D.R. Thal, E. Capetillo-Zarate, K. Del Tredici, and H. Braak The development of amyloid beta protein deposits in the aged brain Sci Aging Knowledge Environ 2006 2006 re1
3. B.T. Hyman, C.H. Phelps, T.G. Beach, E.H. Bigio, N.J. Cairns, and M.C. Carrillo et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease Alzheimers Dement 8 2012 1 13
4. H. Hampel, D. Prvulovic, S. Teipel, F. Jessen, C. Luckhaus, and L. Frölich et al. The future of Alzheimer's disease: the next 10 years Prog Neurobiol 95 2011 718 728
5. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 2010 131 144
6. H. Hampel, R. Frank, K. Broich, S.J. Teipel, R.G. Katz, and J. Hardy et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat Rev Drug Discov 9 2010 560 574
7. H. Hampel, S. Lista, and Z.S. Khachaturian Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot Alzheimers Dement 8 2012 312 336
8. M. Ewers, R.A. Sperling, W.E. Klunk, M.W. Weiner, and H. Hampel Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia Trends Neurosci 34 2011 430 442
9. J.Q. Trojanowski, and H. Hampel Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention Prog Neurobiol 95 2011 491 495
10. P. Nicotera, and H. Hampel Perspectives of worldwide translational biomarker research in neurodegenerative diseases Prog Neurobiol 95 2011 496 497
11. L. Bertram, and H. Hampel The role of genetics for biomarker development in neurodegeneration Prog Neurobiol 95 2011 501 504
12. H. Hampel, and S. Lista Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge Nat Rev Neurol 8 2012 598 600
13. K. Henriksen, S.E. O'Bryant, H. Hampel, J.Q. Trojanowski, T.J. Montine, and A. Jeromin et al. The future of blood-based biomarkers for Alzheimer's disease Alzheimers Dement 2013 10.1016/j.jalz.2013.01.013 pii: S1552-5260(13)00045-9
14. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, and R.C. Green et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 8 2012 S1 S68
15. G.B. Frisoni Alzheimer's disease neuroimaging initiative in Europe Alzheimers Dement 6 2010 280 285
16. M.C. Carrillo, L.J. Bain, G.B. Frisoni, and M.W. Weiner Worldwide Alzheimer's disease neuroimaging initiative Alzheimers Dement 8 2012 337 342
17. H. Hampel, and S. Lista Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement J Nutr Health Aging 17 2013 54 63
18. B. Vellas, M.C. Carrillo, C. Sampaio, H.R. Brashear, E. Siemers, and H. Hampel et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force Alzheimers Dement 9 2013 438 444
19. K. Blennow Biomarkers in Alzheimer's disease drug development Nat Med 16 2010 1218 1222
20. P.J. Visser, S. Vos, I. van Rossum, and P. Scheltens Comparison of International Working Group criteria and National Institute on Aging-Alzheimer's Association criteria for Alzheimer's disease Alzheimers Dement 8 2012 560 563
21. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746 (Pubitemid 47058377)
22. J.L. Cummings, B. Dubois, J.L. Molinuevo, and P. Scheltens International Work Group criteria for the diagnosis of Alzheimer disease Med Clin North Am 97 2013 363 368
23. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, and P. Barberger-Gateau et al. Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
24. J. Cummings Alzheimer's disease diagnostic criteria: practical applications Alzheimers Res Ther 4 2012 35
25. M. Isaac, S. Vamvakas, E. Abadie, B. Jonsson, C. Gispen, and L. Pani Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: cerebrospinal fluid related biomarkers for drug affecting amyloid burden-regulatory considerations by European Medicines Agency focusing in improving benefit/risks in regulatory trials Eur Neuropsychopharmacol 21 2011 781 788
26. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
27. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
28. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
29. T. Jonsson, J.K. Atwal, S. Steinberg, J. Snaedal, P.V. Jonsson, and S. Bjornsson et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline Nature 488 2012 96 99
30. C.R. Jack Jr., M.S. Albert, D.S. Knopman, G.M. McKhann, R.A. Sperling, and M.C. Carrillo et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 257 262
31. M. Sarazin, L.C. de Souza, S. Lehéricy, and B. Dubois Clinical and research diagnostic criteria for Alzheimer's disease Neuroimaging Clin N Am 22 2012 23 32 viii
32. L. Bertram, and R.E. Tanzi The genetics of Alzheimer's disease Prog Mol Biol Transl Sci 107 2012 79 100
33. L. Bertram, C.M. Lill, and R.E. Tanzi The genetics of Alzheimer disease: back to the future Neuron 68 2010 270 281
34. B.J. Traynor, and A.B. Singleton Nature versus nurture: death of a dogma, and the road ahead Neuron 68 2010 196 200
35. L. Bertram Alzheimer's genetics in the GWAS era: a continuing story of 'replications and refutations' Curr Neurol Neurosci Rep 11 2011 246 253
36. M. Cruts, J. Theuns, and C. Van Broeckhoven Locus-specific mutation databases for neurodegenerative brain diseases Hum Mutat 33 2012 1340 1344
37. H. Steiner, R. Fluhrer, and C. Haass Intramembrane proteolysis by gamma-secretase J Biol Chem 283 2008 29627 29631
38. E. Levy-Lahad, W. Wasco, P. Poorkaj, D.M. Romano, J. Oshima, and W.H. Pettingell et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus Science 269 1995 973 977
39. E.I. Rogaev, R. Sherrington, E.A. Rogaeva, G. Levesque, M. Ikeda, and Y. Liang et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene Nature 376 1995 775 778
40. R.E. Tanzi, and L. Bertram Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective Cell 120 2005 545 555 (Pubitemid 40269768)
41. C. Pottier, D. Hannequin, S. Coutant, A. Rovelet-Lecrux, D. Wallon, and S. Rousseau et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease Mol Psychiatry 17 2012 875 879
42. W.J. Strittmatter, A.M. Saunders, D. Schmechel, M. Pericak-Vance, J. Enghild, and G.S. Salvesen et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease Proc Natl Acad Sci USA 90 1993 1977 1981 (Pubitemid 23069980)
43. E.H. Corder, A.M. Saunders, N.J. Risch, W.J. Strittmatter, D.E. Schmechel, and P.C. Gaskell Jr. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease Nat Genet 7 1994 180 184 (Pubitemid 24174658)
44. N. Elshourbagy, W. Liao, R. Mahley, and J. Taylor Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets Proc Natl Acad Sci USA 82 1985 203 207 (Pubitemid 15168243)
45. C. Lin, Y. Xu, J. Wu, and L. Chan Immunoreactive apolipoprotein E is a widely distributed cellular protein. Immunohistochemical localization of apolipoprotein E in baboon tissues J Clin Invest 78 1986 947 958 (Pubitemid 17177075)
46. J. Boyles, R. Pitas, E. Wilson, R. Mahley, and J. Taylor Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system J Clin Invest 76 1985 1501 1513 (Pubitemid 16193568)
47. M. Nakai, T. Kawamata, T. Taniguchi, K. Maeda, and C. Tanaka Expression of apolipoprotein E mRNA in rat microglia Neurosci Lett 211 1996 41 44 (Pubitemid 26228023)
48. K.L. Youmans, L.M. Tai, E. Nwabuisi-Heath, L. Jungbauer, T. Kanekiyo, and M. Gan et al. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease J Biol Chem 287 2012 41774 41786
49. C.C. Liu, T. Kanekiyo, H. Xu, G. Bu, and E. Apolipoprotein Alzheimer disease: risk, mechanisms and therapy Nat Rev Neurol 9 2013 106 118
50. D.R. Thal, A. Papassotiropoulos, T.C. Saido, W.S. Griffin, R.E. Mrak, and H. Kölsch et al. Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease Acta Neuropathol 120 2010 169 183
51. L. Bertram, M.B. McQueen, K. Mullin, D. Blacker, and R.E. Tanzi Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database Nat Genet 39 2007 17 23 (Pubitemid 46026496)
52. D. Harold, R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, and M.L. Hamshere et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease Nat Genet 41 2009 1088 1093
53. J.C. Lambert, S. Heath, G. Even, D. Campion, K. Sleegers, and M. Hiltunen et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease Nat Genet 41 2009 1094 1099
54. S. Seshadri, A.L. Fitzpatrick, M.A. Ikram, A.L. DeStefano, V. Gudnason, and M. Boada et al. Genome-wide analysis of genetic loci associated with Alzheimer disease J Am Med Assoc 303 2010 1832 1840
55. P. Hollingworth, D. Harold, R. Sims, A. Gerrish, J.C. Lambert, and M.M. Carrasquillo et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease Nat Genet 43 2011 429 435
56. A.C. Naj, G. Jun, G.W. Beecham, L.S. Wang, B.N. Vardarajan, and J. Buros et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease Nat Genet 43 2011 436 441
57. T. Zetzsche, D. Rujescu, J. Hardy, and H. Hampel Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease Expert Rev Mol Diagn 10 2010 667 690
58. L. Jones, P.A. Holmans, M.L. Hamshere, D. Harold, V. Moskvina, and D. Ivanov et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease PLoS ONE 5 2010 e13950
59. T. Jonsson, H. Stefansson, S. Steinberg, I. Jonsdottir, P.V. Jonsson, and J. Snaedal et al. Variant of TREM2 associated with the risk of Alzheimer's disease N Engl J Med 368 2013 107 116
60. R. Guerreiro, A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaeva, and E. Majounie et al. TREM2 variants in Alzheimer's disease N Engl J Med 368 2013 117 127
61. H. Neumann, and M.J. Daly Variant TREM2 as risk factor for Alzheimer's disease N Engl J Med 368 2013 182 184
62. H. Zetterberg, K. Tullhög, O. Hansson, L. Minthon, E. Londos, and K. Blennow Low incidence of post-lumbar puncture headache in 1089 consecutive memory clinic patients Eur Neurol 63 2010 326 330
63. N. Andreasen, L. Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele, and B. Winblad et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice Arch Neurol 58 2001 373 379 (Pubitemid 32217453)
64. F. Tabaraud, J.P. Leman, A.M. Milor, J.M. Roussie, G. Barrière, and M. Tartary et al. Alzheimer CSF biomarkers in routine clinical setting Acta Neurol Scand 125 2012 416 423
65. R. Dodel, A. Rominger, P. Bartenstein, F. Barkhof, K. Blennow, and S. Förster et al. Intravenous immunoglobulins for the treatment of mild to moderate Alzheimer's disease: a phase II, randomised, double-blind, placebo-controlled trial Lancet Neurol 12 2013 233 243
66. B. Winblad, N. Andreasen, L. Minthon, A. Floesser, G. Imbert, and T. Dumortier et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study Lancet Neurol 11 2012 597 604
67. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, and J. Harrison et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol 7 2008 779 786
68. M. Vandermeeren, M. Mercken, E. Vanmechelen, J. Six, A. van de Voorde, and J.J. Martin et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay J Neurochem 61 1993 1828 1834 (Pubitemid 23317209)
69. K. Blennow, A. Wallin, H. Agren, C. Spenger, J. Siegfried, and E. Vanmechelen Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease Mol Chem Neuropathol 26 1995 231 245 (Pubitemid 26002016)
70. R. Motter, C. Vigo-Pelfrey, D. Kholodenko, R. Barbour, K. Johnson-Wood, and D. Galasko et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease Ann Neurol 38 1995 643 648
71. K. Blennow Cerebrospinal fluid protein biomarkers for Alzheimer's disease NeuroRx 1 2004 213 225 (Pubitemid 46589353)
72. K. Blennow, and H. Hampel Cerebrospinal fluid markers for incipient Alzheimer's disease Lancet Neurol 2 2003 605 613 (Pubitemid 37162569)
73. H. Hampel, S.J. Teipel, T. Fuchsberger, N. Andreasen, J. Wiltfang, and M. Otto et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment Mol Psychiatry 9 2004 705 710 (Pubitemid 38932175)
74. K. Koopman, N. Le Bastard, J.J. Martin, G. Nagels, P.P. De Deyn, and S. Engelborghs Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P) Neurochem Int 55 2009 214 218
75. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413
76. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 2006 228 234 (Pubitemid 43238346)
77. B.J. Snider, A.M. Fagan, C. Roe, A.R. Shah, E.A. Grant, and C. Xiong et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type Arch Neurol 66 2009 638 645
78. P.J. Visser, F. Verhey, D.L. Knol, P. Scheltens, L.O. Wahlund, and Y. Freund-Levi et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study Lancet Neurol 8 2009 619 627
79. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment J Am Med Assoc 302 2009 385 393
80. I. Skoog, P. Davidsson, O. Aevarsson, H. Vanderstichele, E. Vanmechelen, and K. Blennow Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds Dement Geriatr Cogn Disord 15 2003 169 176 (Pubitemid 36206647)
81. D.R. Gustafson, I. Skoog, L. Rosengren, H. Zetterberg, and K. Blennow Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women J Neurol Neurosurg Psychiatry 78 2007 461 464 (Pubitemid 46662891)
82. E. Stomrud, O. Hansson, K. Blennow, L. Minthon, and E. Londos Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly Dement Geriatr Cogn Disord 24 2007 118 124 (Pubitemid 47094071)
83. M. Moonis, J.M. Swearer, M.P. Dayaw, P. St George-Hyslop, E. Rogaeva, and T. Kawarai et al. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline Neurology 65 2005 323 325 (Pubitemid 41022387)
84. J.M. Ringman, S.G. Younkin, D. Pratico, W. Seltzer, G.M. Cole, and D.H. Geschwind et al. Biochemical markers in persons with preclinical familial Alzheimer disease Neurology 71 2008 85 92
85. R.J. Bateman, C. Xiong, T.L. Benzinger, A.M. Fagan, A. Goate, and N.C. Fox et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease N Engl J Med 367 2012 795 804
86. E.M. Reiman, Y.T. Quiroz, A.S. Fleisher, K. Chen, C. Velez-Pardo, and M. Jimenez-Del-Rio et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study Lancet Neurol 11 2012 1048 1056
87. R. Tarawneh, and D.M. Holtzman Biomarkers in translational research of Alzheimer's disease Neuropharmacology 59 2010 310 322
88. M. Shoji, E. Matsubara, M. Kanai, M. Watanabe, T. Nakamura, and Y. Tomidokoro et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease J Neurol Sci 158 1998 134 140 (Pubitemid 28342076)
89. V. Welge, O. Fiege, P. Lewczuk, B. Mollenhauer, H. Esselmann, and H.W. Klafki et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease J Neural Transm 116 2009 203 212
90. A.M. Fagan, C.M. Roe, C. Xiong, M.A. Mintun, J.C. Morris, and D.M. Holtzman Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults Arch Neurol 64 2007 343 349 (Pubitemid 46425688)
91. G. Li, I. Sokal, J.F. Quinn, J.B. Leverenz, M. Brodey, and G.D. Schellenberg et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study Neurology 69 2007 631 639 (Pubitemid 47256004)
92. M. Brys, E. Pirraglia, K. Rich, S. Rolstad, L. Mosconi, and R. Switalski et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment Neurobiol Aging 30 2009 682 690
93. M. Riemenschneider, N. Lautenschlager, S. Wagenpfeil, J. Diehl, A. Drzezga, and A. Kurz Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment Arch Neurol 59 2002 1729 1734 (Pubitemid 35340483)
94. K. Blennow, H. Zetterberg, and A.M. Fagan Fluid biomarkers in Alzheimer disease Cold Spring Harb Perspect Med 2 2012 a006221
95. A. Maddalena, A. Papassotiropoulos, B. Muller-Tillmanns, H.H. Jung, T. Hegi, and R.M. Nitsch et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to b-amyloid peptide 42 Arch Neurol 60 2003 1202 1206 (Pubitemid 37099624)
96. H. Zetterberg, L.O. Wahlund, and K. Blennow Cerebrospinal fluid markers for prediction of Alzheimer's disease Neurosci Lett 352 2003 67 69 (Pubitemid 37412328)
97. A. Olsson, H. Vanderstichele, N. Andreasen, G. de Meyer, A. Wallin, and B. Holmberg et al. Simultaneous measurement of β-amyloid(1-42), tau and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology Clin Chem 51 2005 336 345 (Pubitemid 40175803)
98. P. Lewczuk, J. Kornhuber, H. Vanderstichele, E. Vanmechelen, H. Esselmann, and M. Bibl et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study Neurobiol Aging 29 2008 812 818 (Pubitemid 351601894)
99. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
100. P. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, and O. Hansson Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch Gen Psychiatry 69 2012 98 106
101. I.A. van Rossum, S.J. Vos, L. Burns, D.L. Knol, P. Scheltens, and H. Soininen et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology Neurology 79 2012 1809 1816
102. C.E. Teunissen, N.A. Verwey, M.I. Kester, K. van Uffelen, and M.A. Blankenstein Standardization of assay procedures for analysis of the CSF biomarkers amyloid β((1-42)) tau, and phosphorylated tau in Alzheimer's disease: report of an International Workshop Int J Alzheimers Dis 2010 10.4061/2010/635053 pii: 635053
103. H. Vanderstichele, M. Bibl, S. Engelborghs, N. Le Bastard, P. Lewczuk, and J.L. Molinuevo et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative Alzheimers Dement 8 2012 65 73
104. N. Mattsson, and H. Zetterberg What is a certified reference material Biomark Med 6 2012 369 370
105. N. Mattsson, I. Zegers, U. Andreasson, M. Bjerke, M.A. Blankenstein, and R. Bowser et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42 Biomark Med 6 2012 409 417
106. N. Mattsson, U. Andreasson, M.C. Carrillo, S. Persson, L.M. Shaw, and I. Zegers et al. Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers Biomark Med 6 2012 401 407
107. N. Mattsson, U. Andreasson, S. Persson, M.C. Carrillo, S. Collins, and S. Chalbot et al. CSF biomarker variability in the Alzheimer's association quality control program Alzheimers Dement 9 2013 251 261
108. A.M. Fagan, and R.J. Perrin Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease Biomark Med 6 2012 455 476
109. R. Kaddurah-Daouk, B. Kristal, and R. Weinshilboum Metabolomics: a global biochemical approach to drug response and disease Annu Rev Pharmacol Toxicol 48 2008 653 683 (Pubitemid 351738167)
110. S. Patel, R.J. Shah, P. Coleman, and M. Sabbagh Potential peripheral biomarkers for the diagnosis of Alzheimer's disease Int J Alzheimers Dis 2011 10.4061/2011/572495 pii: 572495
111. E. Kaiser, P. Schoenknecht, S. Kassner, W. Hildebrandt, R. Kinscherf, and J. Schroeder Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer's disease Neurodegener Dis 7 2010 251 259
112. C. Czech, P. Berndt, K. Busch, O. Schmitz, J. Wiemer, and V. Most et al. Metabolite profiling of Alzheimer's disease cerebrospinal fluid PLoS ONE 7 2012 e31501
113. M. van Oijen, A. Hofman, H.D. Soares, P.J. Koudstaal, and M.M. Breteler Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study Lancet Neurol 5 2006 655 660 (Pubitemid 44062411)
114. R. Mayeux, L.S. Honig, M.X. Tang, J. Manly, Y. Stern, and N. Schupf et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk Neurology 61 2003 1185 1190 (Pubitemid 37377535)
115. O. Hansson, H. Zetterberg, E. Vanmechelen, H. Vanderstichele, U. Andreasson, and E. Londos et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment Neurobiol Aging 31 2010 357 367
116. O.L. Lopez, L.H. Kuller, P.D. Mehta, J.T. Becker, H.M. Gach, and R.A. Sweet et al. Plasma amyloid levels and the risk of AD in normal subjects in the cardiovascular health study Neurology 70 2008 1664 1671 (Pubitemid 351644132)
117. J. Sundelof, V. Giedraitis, M.C. Irizarry, J. Sundstrom, E. Ingelsson, and E. Ronnemaa et al. Plasma beta amyloid and the risk of Alzheimer disease and dementia in elderly men: a prospective, population-based cohort study Arch Neurol 65 2008 256 263 (Pubitemid 351240790)
118. N.R. Graff-Radford, J.E. Crook, J. Lucas, B.F. Boeve, D.S. Knopman, and R.J. Ivnik et al. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease Arch Neurol 64 2007 354 362 (Pubitemid 46425689)
119. K. Yaffe, A. Weston, N.R. Graff-Radford, S. Satterfield, E.M. Simonsick, and S.G. Younkin et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline J Am Med Assoc 305 2011 261 266
120. R. Mayeux, M.X. Tang, D.M. Jacobs, J. Manly, K. Bell, and C. Merchant et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease Ann Neurol 46 1999 412 416 (Pubitemid 29416281)
121. A. Koyama, O.I. Okereke, T. Yang, D. Blacker, D.J. Selkoe, and F. Grodstein Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis Arch Neurol 69 2012 824 831
122. J. Randall, E. Mortberg, G.K. Provuncher, D.R. Fournier, D.C. Duffy, and S. Rubertsson et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study Resuscitation 84 2013 351 356
123. C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele, and E. Vanmechelen et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke Neurosci Lett 297 2001 187 190 (Pubitemid 32011305)
124. C. Rosén, O. Hansson, K. Blennow, and H. Zetterberg Fluid biomarkers in Alzheimer's disease - current concepts Mol Neurodegener 8 2013 20
125. H. Zetterberg, D. Wilson, U. Andreasson, L. Minthon, K. Blennow, and J. Randall et al. Plasma tau levels in Alzheimer's disease Alzheimers Res Ther 5 2013 9
126. S. Ray, P.J. Reddy, R. Jain, K. Gollapalli, A. Moiyadi, and S. Srivastava Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead Proteomics 11 2011 2139 2161
127. S. Lista, F. Faltraco, D. Prvulovic, and H. Hampel Blood and plasma-based proteomic biomarker research in Alzheimer's disease Prog Neurobiol 101-102 2013 1 17
128. M. Thambisetty, and S. Lovestone Blood-based biomarkers of Alzheimer's disease: challenging but feasible Biomark Med 4 2010 65 79
129. S. Ray, M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, and K. Blennow et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins Nat Med 13 2007 1359 1362 (Pubitemid 350073592)
130. W.T. Hu, D.M. Holtzman, A.M. Fagan, L.M. Shaw, R. Perrin, and S.E. Arnold et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease Neurology 79 2012 897 905
131. T. Wyss-Coray Inflammation in Alzheimer disease: driving force, bystander or beneficial response Nat Med 12 2006 1005 1015 (Pubitemid 44353380)
132. T. Wyss-Coray, and J. Rogers Inflammation in Alzheimer disease - a brief review of the basic science and clinical literature Cold Spring Harb Perspect Med 2 2012 a006346
133. M. Bjorkqvist, M. Ohlsson, L. Minthon, and O. Hansson Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease PLoS ONE 7 2012 e29868
134. J.D. Doecke, S.M. Laws, N.G. Faux, W. Wilson, S.C. Burnham, and C.P. Lam et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease Arch Neurol 69 2012 1318 1325
135. S.E. O'Bryant, G. Xiao, R. Barber, R. Huebinger, K. Wilhelmsen, and M. Edwards et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI PLoS ONE 6 2011 e28092
136. D. Galasko, and T.E. Golde Biomarkers for Alzheimer's disease in plasma, serum and blood - conceptual and practical problems Alzheimers Res Ther 5 2013 10
137. S. Lista, F. Faltraco, and H. Hampel Biological and methodical challenges of blood-based proteomics in the field of neurological research Prog Neurobiol 101-102 2013 18 34
138. R. Apweiler, C. Aslanidis, T. Deufel, A. Gerstner, J. Hansen, and D. Hochstrasser et al. Approaching clinical proteomics: current state and future fields of application in fluid proteomics Clin Chem Lab Med 47 2009 724 744
139. G.S. Omenn, D.J. States, M. Adamski, T.W. Blackwell, R. Menon, and H. Hermjakob et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database Proteomics 5 2005 3226 3245 (Pubitemid 41192032)
140. G.S. Omenn Data management and data integration in the HUPO plasma proteome project Methods Mol Biol 696 2011 247 257
141. L. Clerx, P.J. Visser, F. Verhey, and P. Aalten New MRI markers for Alzheimer's disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements J Alzheimers Dis 29 2012 405 429
142. N.C. Fox, R.S. Black, S. Gilman, M.N. Rossor, S.G. Griffith, and L. Jenkins et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease Neurology 64 2005 1563 1572 (Pubitemid 40617692)
143. C.R. Jack Jr., M. Slomkowski, S. Gracon, T.M. Hoover, J.P. Felmlee, and K. Stewart et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD Neurology 60 2003 253 260 (Pubitemid 36152018)
144. D. Wilkinson, N.C. Fox, F. Barkhof, R. Phul, O. Lemming, and P. Scheltens Memantine and brain atrophy in Alzheimer's disease: a 1-year randomized controlled trial J Alzheimers Dis 29 2012 459 469
145. G.B. Frisoni, and C.R. Jack Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use Alzheimers Dement 7 2011 171 174
146. C.R. Jack Jr., F. Barkhof, M.A. Bernstein, M. Cantillon, P.E. Cole, and C. Decarli Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease Alzheimers Dement 7 2011 474-85.e4
147. L.C. De Souza, M. Chupin, M. Bertoux, S. Lehéricy, B. Dubois, and F. Lamari et al. Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia J. Alzheimers Dis 36 2013 57 66
148. M.P. Laakso, K. Partanen, P. Riekkinen, M. Lehtovirta, E.L. Helkala, and M. Hallikainen et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study Neurology 46 1996 678 681 (Pubitemid 26099632)
149. M. Hashimoto, H. Kitagaki, T. Imamura, N. Hirono, T. Shimomura, and H. Kazui et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies: a volumetric MRI study Neurology 51 1998 357 362 (Pubitemid 28406306)
150. P. Videbech, and B. Ravnkilde Hippocampal volume and depression: a meta-analysis of MRI studies Am J Psychiatry 161 2004 1957 1966 (Pubitemid 39441394)
151. N.C. Fox, W.R. Crum, R.I. Scahill, J.M. Stevens, J.C. Janssen, and M.N. Rossor Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images Lancet 358 2001 201 205 (Pubitemid 32718544)
152. H.G. Schnack, N.E. van Haren, H.E. Hulshoff Pol, M. Picchioni, M. Weisbrod, and H. Sauer et al. Reliability of brain volumes from multicenter MRI acquisition: a calibration study Hum Brain Map 22 2004 312 320 (Pubitemid 39045307)
153. A.D. Smith, S.M. Smith, C.A. de Jager, P. Whitbread, C. Johnston, and G. Agacinski et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial PLoS ONE 5 2010 e12244
154. J. Ashburner A fast diffeomorphic image registration algorithm Neuroimage 38 2007 95 113 (Pubitemid 47440133)
155. G. Douaud, H. Refsum, C.A. de Jager, R. Jacoby, T.E. Nichols, and S.M. Smith et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment Proc Natl Acad Sci USA 110 2013 9523 9528
156. M. Dyrba, M. Ewers, M. Wegrzyn, I. Kilimann, C. Plant, and A. Oswald et al. Robust automated detection of microstructural white matter degeneration in Alzheimer's disease using machine learning classification of multicenter DTI data PLoS ONE 8 2013 e64925
157. C. Plant, S.J. Teipel, A. Oswald, C. Bohm, T. Meindl, and J. Mourao-Miranda et al. Automated detection of brain atrophy patterns based on MRI for the prediction of Alzheimer's disease Neuroimage 50 2010 162 174
158. S. Klöppel, C.M. Stonnington, C. Chu, B. Draganski, R.I. Scahill, and J.D. Rohrer et al. Automatic classification of MR scans in Alzheimer's disease Brain 131 2008 681 689 (Pubitemid 351294712)
159. C. Zarow, H.V. Vinters, W.G. Ellis, M.W. Weiner, D. Mungas, and L. White et al. Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia Ann Neurol 57 2005 896 903 (Pubitemid 40798628)
160. M. Bobinski, M.J. de Leon, J. Wegiel, S. Desanti, A. Convit, and L.A. Saint Louis et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease Neuroscience 95 2000 721 725
161. S.H. Freeman, R. Kandel, L. Cruz, A. Rozkalne, K. Newell, and M.P. Frosch et al. Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease J Neuropathol Exp Neurol 67 2008 1205 1212
162. L.T. Grinberg, E. Amaro Jr., A.V. da Silva, R.E. da Silva, J.R. Sato, and D.D. dos Santos et al. Improved detection of incipient vascular changes by a biotechnological platform combining post mortem MRI in situ with neuropathology J Neurol Sci 283 2009 2 8
163. M.E. Murray, K.F. Bieniek, M. Banks Greenberg, M. Dejesus-Hernandez, N.J. Rutherford, and M. van Blitterswijk et al. Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72 Acta Neuropathol 2013 10.1007/s00401-013-1161-2
164. V.L. Villemagne, S. Burnham, P. Bourgeat, B. Brown, K.A. Ellis, and O. Salvado et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study Lancet Neurol 12 2013 357 367
165. C. Westerberg, A. Mayes, S.M. Florczak, Y. Chen, J. Creery, and T. Parrish et al. Distinct medial temporal contributions to different forms of recognition in amnestic mild cognitive impairment and Alzheimer's disease Neuropsychologia 2013 10.1016/j.neuropsychologia.2013.06.025
166. J.C. Morris, C.M. Roe, E.A. Grant, D. Head, M. Storandt, and A.M. Goate et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease Arch Neurol 66 2009 1469 1475
167. P. Giannakopoulos, E. Kovari, G. Gold, A. von Gunten, P.R. Hof, and C. Bouras Pathological substrates of cognitive decline in Alzheimer's disease Front Neurol Neurosci 24 2009 20 29
168. S.G. Mueller, and M.W. Weiner Selective effect of age, Apo e4, and Alzheimer's disease on hippocampal subfields Hippocampus 19 2009 558 564
169. B.J. Hanseeuw, K. Van Leemput, M. Kavec, C. Grandin, X. Seron, and A. Ivanoiu Mild cognitive impairment: differential atrophy in the hippocampal subfields AJNR Am J Neuroradiol 32 2011 1658 1661
170. L.E. Wisse, L. Gerritsen, J.J. Zwanenburg, H.J. Kuijf, P.R. Luijten, and G.J. Biessels et al. Subfields of the hippocampal formation at 7 T MRI: in vivo volumetric assessment Neuroimage 61 2012 1043 1049
171. 1 Radiology 261 2011 199 209
172. G.A. Kerchner, G.K. Deutsch, M. Zeineh, R.F. Dougherty, M. Saranathan, and B.K. Rutt Hippocampal CA1 apical neuropil atrophy and memory performance in Alzheimer's disease Neuroimage 63 2012 194 202
173. R.T. Bartus, R.L. Dean, M.J. Pontecorvo, and C. Flicker The cholinergic hypothesis: a historical overview, current perspective, and future directions Ann N Y Acad Sci 444 1985 332 358 (Pubitemid 15237840)
174. M. Mesulam The cholinergic lesion of Alzheimer's disease: pivotal factor or side show Learn Mem 11 2004 43 49 (Pubitemid 38167057)
175. S.J. Teipel, W.H. Flatz, H. Heinsen, A.L. Bokde, S.O. Schoenberg, and S. Stockel et al. Measurement of basal forebrain atrophy in Alzheimer's disease using MRI Brain 128 2005 2626 2644 (Pubitemid 41552947)
176. L. Zaborszky, L. Hoemke, H. Mohlberg, A. Schleicher, K. Amunts, and K. Zilles Stereotaxic probabilistic maps of the magnocellular cell groups in human basal forebrain Neuroimage 42 2008 1127 1141
177. S.J. Teipel, R. Buchert, J. Thome, H. Hampel, and J. Pahnke Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression Prog Neurobiol 95 2011 547 556
178. S.J. Teipel, E. Kaza, S. Hadlich, A. Bauer, T. Brüning, and A.S. Plath et al. Automated detection of amyloid-β-related cortical and subcortical signal changes in a transgenic model of Alzheimer's disease using high-field MRI J Alzheimers Dis 23 2011 221 237
179. M.F. Falangola, V.V. Dyakin, S.P. Lee, A. Bogart, J.S. Babb, and K. Duff et al. Quantitative MRI reveals aging-associated T2 changes in mouse models of Alzheimer's disease NMR Biomed 20 2007 343 351 (Pubitemid 46824534)
180. S.P. Lee, M.F. Falangola, R.A. Nixon, K. Duff, and J.A. Helpern Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents Magn Reson Med 52 2004 538 544 (Pubitemid 39108965)
181. A. Bertrand, A. Pasquier, A. Petiet, C. Wiggins, A. Kraska, and N. Joseph-Mathurin et al. Micro-MRI study of cerebral aging: ex vivo detection of hippocampal subfield reorganization, microhemorrhages and amyloid plaques in mouse lemur primates PLoS ONE 8 2013 e56593
182. T. Nakada, H. Matsuzawa, H. Igarashi, Y. Fujii, and I.L. Kwee In vivo visualization of senile-plaque-like pathology in Alzheimer's disease patients by MR microscopy on a 7 T system J Neuroimaging 18 2008 125 129 (Pubitemid 351463961)
183. P.J. Basser, and D.K. Jones Diffusion-tensor MRI: theory, experimental design and data analysis - a technical review NMR Biomed 15 2002 456 467 (Pubitemid 36054509)
184. L. O'Dwyer, F. Lamberton, A.L. Bokde, M. Ewers, Y.O. Faluyi, and C. Tanner et al. Multiple indices of diffusion identifies white matter damage in mild cognitive impairment and Alzheimer's disease PLoS ONE 6 2011 e21745
185. C.P. Hess Update on diffusion tensor imaging in Alzheimer's disease Magn Reson Imaging Clin N Am 17 2009 215 224
186. T.C. Chua, W. Wen, M.J. Slavin, and P.S. Sachdev Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease: a review Curr Opin Neurol 21 2008 83 92
187. M. Bozzali, and A. Cherubini Diffusion tensor MRI to investigate dementias: a brief review Magn Reson Imaging 25 2007 969 977 (Pubitemid 47081370)
188. C. Pierpaoli, and P.J. Basser Toward a quantitative assessment of diffusion anisotropy Magn Reson Med 36 1996 893 906 (Pubitemid 26396817)
189. D.K. Jones Studying connections in the living human brain with diffusion MRI Cortex 44 2008 936 952
190. M. Takahashi, D.B. Hackney, G. Zhang, S.L. Wehrli, A.C. Wright, and W.T. O'Brien et al. Magnetic resonance microimaging of intraaxonal water diffusion in live excised lamprey spinal cord Proc Natl Acad Sci USA 99 2002 16192 16196 (Pubitemid 35462771)
191. Y. Liu, G. Spulber, K.K. Lehtimäki, M. Könönen, I. Hallikainen, and H. Gröhn et al. Diffusion tensor imaging and tract-based spatial statistics in Alzheimer's disease and mild cognitive impairment Neurobiol Aging 32 2011 1558 1571
192. D. Medina, L. DeToledo-Morrell, F. Urresta, J.D. Gabrieli, M. Moseley, and D. Fleischman et al. White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study Neurobiol Aging 27 2006 663 672
193. T.C. Chua, W. Wen, X. Chen, N. Kochan, M.J. Slavin, and J.N. Trollor et al. Diffusion tensor imaging of the posterior cingulate is a useful biomarker of mild cognitive impairment Am J Geriatr Psychiatry 17 2009 602 613
194. J. Huang, R.P. Friedland, and A.P. Auchus Diffusion tensor imaging of normal-appearing white matter in mild cognitive impairment and early Alzheimer disease: preliminary evidence of axonal degeneration in the temporal lobe AJNR Am J Neuroradiol 28 2007 1943 1948 (Pubitemid 350174740)
195. M. Bozzali, A. Falini, M. Franceschi, M. Cercignani, M. Zuffi, and G. Scotti et al. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging J Neurol Neurosurg Psychiatry 72 2002 742 746 (Pubitemid 34557017)
196. G. Douaud, S. Jbabdi, T.E. Behrens, R.A. Menke, A. Gass, and A.U. Monsch et al. DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease Neuroimage 55 2011 880 890
197. D.B. Ennis, and G. Kindlmann Orthogonal tensor invariants and the analysis of diffusion tensor magnetic resonance images Magn Reson Med 55 2006 136 146 (Pubitemid 43062937)
198. N.H. Stricker, B.C. Schweinsburg, L. Delano-Wood, C.E. Wierenga, K.J. Bangen, and K.Y. Haaland et al. Decreased white matter integrity in late-myelinating fiber pathways in Alzheimer's disease supports retrogenesis Neuroimage 45 2009 10 16
199. S.J. Teipel, R. Stahl, O. Dietrich, S.O. Schoenberg, R. Perneczky, and A.L. Bokde et al. Multivariate network analysis of fiber tract integrity in Alzheimer's disease Neuroimage 34 2007 985 995 (Pubitemid 46394457)
200. M. Giannelli, G. Belmonte, N. Toschi, I. Pesaresi, P. Ghedin, and A.C. Traino et al. Technical note: DTI measurements of fractional anisotropy and mean diffusivity at 1.5 T: comparison of two radiofrequency head coils with different functional designs and sensitivities Med Phys 38 2011 3205 3211
201. C.E. Sexton, U.G. Kalu, N. Filippini, C.E. Mackay, and K.P. Ebmeier A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease Neurobiol Aging 32 2322 2011 e5 e18
202. S.J. Teipel, M. Wegrzyn, T. Meindl, G. Frisoni, A.L. Bokde, and A. Fellgiebel et al. Anatomical MRI and DTI in the diagnosis of Alzheimer's disease: a European Multicenter Study J Alzheimers Dis 31 2012 S33 S47
203. A.L. Alexander, K.M. Hasan, M. Lazar, J.S. Tsuruda, and D.L. Parker Analysis of partial volume effects in diffusion-tensor MRI Magn Reson Med 45 2001 770 780 (Pubitemid 32402019)
204. M. Giannelli, N. Toschi, L. Passamonti, M. Mascalchi, S. Diciotti, and C. Tessa Diffusion kurtosis and diffusion-tensor MR imaging in Parkinson disease Radiology 265 2012 645 646
205. E. Fieremans, J.H. Jensen, and J.A. Helpern White matter characterization with diffusional kurtosis imaging Neuroimage 58 2011 177 188
206. J.H. Jensen, and J.A. Helpern MRI quantification of non-Gaussian water diffusion by kurtosis analysis NMR Biomed 23 2010 698 710
207. E.S. Hui, M.M. Cheung, L. Qi, and E.X. Wu Advanced MR diffusion characterization of neural tissue using directional diffusion kurtosis analysis Conf Proc IEEE Eng Med Biol Soc 2008 2008 3941 3944 10.1109/IEMBS.2008.4650072
208. V.J. Wedeen, R.P. Wang, J.D. Schmahmann, T. Benner, W.Y. Tseng, and G. Dai et al. Diffusion spectrum magnetic resonance imaging (DSI) tractography of crossing fibers Neuroimage 41 2008 1267 1277
209. D.C. Alexander Multiple-fiber reconstruction algorithms for diffusion MRI Ann N Y Acad Sci 1064 2005 113 133 (Pubitemid 43030953)
210. Y. Assaf, T. Blumenfeld-Katzir, Y. Yovel, and P.J. Basser AxCaliber: a method for measuring axon diameter distribution from diffusion MRI Magn Reson Med 59 2008 1347 1354 (Pubitemid 351813264)
211. Y. Assaf, and P.J. Basser Composite hindered and restricted model of diffusion (CHARMED) MR imaging of the human brain Neuroimage 27 2005 48 58 (Pubitemid 40966881)
212. S. De Santis, A. Gabrielli, M. Bozzali, B. Maraviglia, E. Macaluso, and S. Capuani Anisotropic anomalous diffusion assessed in the human brain by scalar invariant indices Magn Reson Med 65 2011 1043 1052
213. D.C. Alexander, P.L. Hubbard, M.G. Hall, E.A. Moore, M. Ptito, and G.J. Parker et al. Orientationally invariant indices of axon diameter and density from diffusion MRI Neuroimage 52 2010 1374 1389
214. S. De Santis, A. Gabrielli, M. Palombo, B. Maraviglia, and S. Capuani Non-Gaussian diffusion imaging: a brief practical review Magn Reson Imaging 29 2011 1410 1416
215. A. Iraji, E. Davoodi-Bojd, H. Soltanian-Zadeh, G.A. Hossein-Zadeh, and Q. Jiang Diffusion kurtosis imaging discriminates patients with white matter lesions from healthy subjects Conf Proc IEEE Eng Med Biol Soc. 2011 2011 2796 2799 10.1109/IEMBS.2011.6090765
216. M.F. Falangola, J.H. Jensen, J.S. Babb, C. Hu, F.X. Castellanos, and A. Di Martino et al. Age-related non-Gaussian diffusion patterns in the prefrontal brain J Magn Reson Imaging 28 2008 1345 1350
217. N. Filippini, B.J. MacIntosh, M.G. Hough, G.M. Goodwin, G.B. Frisoni, and S.M. Smith et al. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele Proc Natl Acad Sci USA 106 2009 7209 7214
218. P.R. Borghesani, L.C. Johnson, A.L. Shelton, E.R. Peskind, E.H. Aylward, and G.D. Schellenberg et al. Altered medial temporal lobe responses during visuospatial encoding in healthy APOE*4 carriers Neurobiol Aging 29 2008 981 991 (Pubitemid 351697985)
219. S.Y. Bookheimer, M.H. Strojwas, M.S. Cohen, A.M. Saunders, M.A. Pericak-Vance, and J.C. Mazziotta et al. Patterns of brain activation in people at risk for Alzheimer's disease N Engl J Med 343 2000 450 456 (Pubitemid 30646483)
220. R.A. Sperling, B.C. Dickerson, M. Pihlajamaki, P. Vannini, P.S. LaViolette, and O.V. Vitolo et al. Functional alterations in memory networks in early Alzheimer's disease Neuromol Med 12 2010 27 43
221. R. Sperling Functional MRI studies of associative encoding in normal aging, mild cognitive impairment, and Alzheimer's disease Ann N Y Acad Sci 1097 2007 146 155 (Pubitemid 47084886)
222. A. Hämäläinen, M. Pihlajamäki, H. Tanila, T. Hänninen, E. Niskanen, and S. Tervo et al. Increased fMRI responses during encoding in mild cognitive impairment Neurobiol Aging 28 2007 1889 1903 (Pubitemid 47539695)
223. A. Golby, G. Silverberg, E. Race, S. Gabrieli, J. O'Shea, and K. Knierim et al. Memory encoding in Alzheimer's disease: an fMRI study of explicit and implicit memory Brain 128 2005 773 787 (Pubitemid 40516915)
224. G. Grön, D. Bittner, B. Schmitz, A.P. Wunderlich, R. Tomczak, and M.W. Riepe Hippocampal activations during repetitive learning and recall of geometric patterns Learn Mem 8 2001 336 345 (Pubitemid 34037577)
225. J.R. Petrella, L. Wang, S. Krishnan, M.J. Slavin, S.E. Prince, and T.T. Tran et al. Cortical deactivation in mild cognitive impairment: high-field-strength functional MR imaging Radiology 245 2007 224 235 (Pubitemid 47417806)
226. S.C. Johnson, T.W. Schmitz, C.H. Moritz, M.E. Meyerand, H.A. Rowley, and A.L. Alexander et al. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment Neurobiol Aging 27 2006 1604 1612 (Pubitemid 44363104)
227. K.A. Celone, V.D. Calhoun, B.C. Dickerson, A. Atri, E.F. Chua, and S.L. Miller et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis J Neurosci 26 2006 10222 10231 (Pubitemid 44527415)
228. T.D. Satterthwaite, L. Green, J. Myerson, J. Parker, M. Ramaratnam, and R.L. Buckner Dissociable but inter-related systems of cognitive control and reward during decision making: evidence from pupillometry and event-related fMRI Neuroimage 37 2007 1017 1031 (Pubitemid 47248303)
229. P. Vannini, T. Hedden, J.A. Becker, C. Sullivan, D. Putcha, and D. Rentz et al. Age and amyloid-related alterations in default network habituation to stimulus repetition Neurobiol Aging 33 2012 1237 1252
230. M. Pihlajamäki, K. O'Keefe, J. O'Brien, D. Blacker, and R.A. Sperling Failure of repetition suppression and memory encoding in aging and Alzheimer's disease Brain Imaging Behav 5 2011 36 44
231. M. Pihlajamäki, K. O'Keefe, L. Bertram, R.E. Tanzi, B.C. Dickerson, and D. Blacker et al. Evidence of altered posteromedial cortical FMRI activity in subjects at risk for Alzheimer disease Alzheimer Dis Assoc Disord 24 2010 28 36
232. M. Pihlajamäki, K.M. DePeau, D. Blacker, and R.A. Sperling Impaired medial temporal repetition suppression is related to failure of parietal deactivation in Alzheimer disease Am J Geriatr Psychiatry 16 2008 283 292
233. A.S. Fleisher, A. Sherzai, C. Taylor, J.B. Langbaum, K. Chen, and R.B. Buxton Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups Neuroimage 47 2009 1678 1690
234. M.D. Greicius, K. Supekar, V. Menon, and R.F. Dougherty Resting-state functional connectivity reflects structural connectivity in the default mode network Cereb Cortex 19 2009 72 78
235. M. Wermke, C. Sorg, A.M. Wohlschläger, and A. Drzezga A new integrative model of cerebral activation, deactivation and default mode function in Alzheimer's disease Eur J Nucl Med Mol Imaging 35 2008 S12 S24
236. K. Wang, M. Liang, L. Wang, L. Tian, X. Zhang, and K. Li et al. Altered functional connectivity in early Alzheimer's disease: a resting-state fMRI study Hum Brain Map 28 2007 967 978 (Pubitemid 47549702)
237. C. Sorg, V. Riedl, M. Mühlau, V.D. Calhoun, T. Eichele, and L. Läer et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease Proc Natl Acad Sci USA 104 2007 18760 18765 (Pubitemid 350210770)
238. M.D. Greicius, G. Srivastava, A.L. Reiss, and V. Menon Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI Proc Natl Acad Sci USA 101 2004 4637 4642 (Pubitemid 38437463)
239. J.R. Petrella, F.C. Sheldon, S.E. Prince, V.D. Calhoun, and P.M. Doraiswamy Default mode network connectivity in stable vs. progressive mild cognitive impairment Neurology 76 2011 511 517
240. J. Kukolja, C.M. Thiel, and G.R. Fink Cholinergic stimulation enhances neural activity associated with encoding but reduces neural activity associated with retrieval in humans J Neurosci 29 2009 8119 8128
241. M.F. Shanks, W.J. McGeown, K.E. Forbes-McKay, G.D. Waiter, M. Ries, and A. Venneri Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease Magn Reson Imaging 25 2007 848 859 (Pubitemid 47081360)
242. R. Goekoop, P. Scheltens, F. Barkhof, and S.A. Rombouts Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation - a pharmacological fMRI study Brain 129 2006 141 157 (Pubitemid 43063766)
243. A.J. Saykin, H.A. Wishart, L.A. Rabin, L.A. Flashman, T.L. McHugh, and A.C. Mamourian et al. Cholinergic enhancement of frontal lobe activity in mild cognitive impairment Brain 127 2004 1574 1583 (Pubitemid 38899410)
244. S.A. Rombouts, F. Barkhof, C.S. Van Meel, and P. Scheltens Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease J Neurol Neurosurg Psychiatry 73 2002 665 671 (Pubitemid 35448850)
245. R.A. Sperling The potential of functional MRI as a biomarker in early Alzheimer's disease Neurobiol Aging 32 2011 S37 S43
246. X. Yang, L. Beason-Held, S.M. Resnick, and B.A. Landman Biological parametric mapping with robust and non-parametric statistics Neuroimage 57 2011 423 430
247. R. Casanova, R. Srikanth, A. Baer, P.J. Laurienti, J.H. Burdette, and S. Hayasaka et al. Biological parametric mapping: a statistical toolbox for multimodality brain image analysis Neuroimage 34 2007 137 143 (Pubitemid 44765265)
248. T.R. Oakes, A.S. Fox, T. Johnstone, M.K. Chung, N. Kalin, and R.J. Davidson Integrating VBM into the General Linear Model with voxelwise anatomical covariates Neuroimage 34 2007 500 508 (Pubitemid 44827773)
249. G. Orrù, W. Pettersson-Yeo, A.F. Marquand, G. Sartori, and A. Mechelli Using Support Machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review Neurosci Biobehav Rev 36 2012 1140 1152
250. D. Zhang, D. Shen, and Alzheimer's Disease Neuroimaging Initiative Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease Neuroimage 59 2012 895 907
251. D. Zhang, D. Shen, and Alzheimer's Disease Neuroimaging Initiative Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers PLoS ONE 7 2012 e33182
252. P.J. Magistretti, and L. Pellerin Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders Ann N Y Acad Sci 777 1996 380 387
253. E. Zamrini, S. De Santi, and M. Tolar Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease Neurobiol Aging 25 2004 685 691 (Pubitemid 38686492)
254. D.H. Silverman, G.W. Small, C.Y. Chang, C.S. Lu, and M.A. Kung De Aburto et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome J Am Med Assoc 286 2001 2120 2127 (Pubitemid 34041597)
255. S. Minoshima, N.L. Foster, A.A. Sima, K.A. Frey, R.L. Albin, and D.E. Kuhl Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation Ann Neurol 50 2001 358 365 (Pubitemid 32848738)
256. A. Drzezga, T. Grimmer, M. Riemenschneider, N. Lautenschlager, H. Siebner, and P. Alexopoulus et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET J Nucl Med 46 2005 1625 1632 (Pubitemid 46211586)
257. L. Mosconi, M. Brys, L. Glodzik-Sobanska, S. De Santi, H. Rusinek, and M.J. de Leon Early detection of Alzheimer's disease using neuroimaging Exp Gerontol 42 2007 129 138 (Pubitemid 44937821)
258. L. Scheef, A. Spottke, M. Daerr, A. Joe, N. Striepens, and H. Kölsch et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment Neurology 79 2012 1332 1339
259. E.M. Reiman, R.J. Caselli, L.S. Yun, K. Chen, D. Bandy, and S. Minoshima et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E N Engl J Med 334 1996 752 758 (Pubitemid 26089356)
260. 123I]IBZM-SPECT for the differential diagnosis of parkinsonism Neurology 79 2012 1314 1322
261. M. Lehmann, P.M. Ghosh, C. Madison, R. Laforce Jr., C. Corbetta-Rastelli, and M.W. Weiner et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease Brain 136 2013 844 858
262. S.J. Teipel, F. Willoch, K. Ishii, K. Bürger, A. Drzezga, and R. Engel et al. Resting state glucose utilization and the CERAD cognitive battery in patients with Alzheimer's disease Neurobiol Aging 27 2006 681 690
263. E.M. Reiman, R.J. Caselli, K. Chen, G.E. Alexander, D. Bandy, and J. Frost Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease Proc Natl Acad Sci USA 98 2001 3334 3339 (Pubitemid 32220846)
264. R. Perneczky, A. Drzezga, J. Diehl-Schmid, G. Schmid, A. Wohlschläger, and S. Kars et al. Schooling mediates brain reserve in Alzheimer's disease: findings of fluoro-deoxy-glucose-positron emission tomography J Neurol Neurosurg Psychiatry 77 2006 1060 1063 (Pubitemid 44338530)
265. S. Förster, V.C. Buschert, H.G. Buchholz, S.J. Teipel, U. Friese, and C. Zach et al. Effects of a 6-month cognitive intervention program on brain metabolism in amnestic mild cognitive impairment and mild Alzheimer's disease J Alzheimers Dis 25 2011 695 706
266. S.J. Teipel, A. Drzezga, P. Bartenstein, H.J. Möller, M. Schwaiger, and H. Hampel Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial Psychopharmacology (Berlin) 187 2006 86 94 (Pubitemid 43876920)
267. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 2004 306 319 (Pubitemid 38269583)
268. C.C. Rowe, and V.L. Villemagne Brain amyloid imaging J Nucl Med 52 2011 1733 1740
269. 18F-AZD4694, an amyloid-β-specific PET radioligand J Nucl Med 53 2012 415 424
270. C.C. Rowe The Centiloid Scale: Standardization of Amyloid Imaging Measures. Abstract 13-18 July 2013 2013 Alzheimer Association International Conference Boston, MA, USA
271. M.D. Ikonomovic, W.E. Klunk, E.E. Abrahamson, C.A. Mathis, J.C. Price, and N.D. Tsopelas et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease Brain 131 2008 1630 1645 (Pubitemid 351806448)
272. C.M. Clark, J.A. Schneider, B.J. Bedell, T.G. Beach, W.B. Bilker, and M.A. Mintun et al. Use of florbetapir-PET for imaging beta-amyloid pathology J Am Med Assoc 305 2011 275 283
273. P.W. Thompson, L. Ye, J.L. Morgenstern, L. Sue, T.G. Beach, and D.J. Judd et al. Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies J Neurochem 109 2009 623 630
274. E.R. Foster, M.C. Campbell, M.A. Burack, J. Hartlein, H.P. Flores, and N.J. Cairns et al. Amyloid imaging of Lewy body-associated disorders Mov Disord 25 2010 2516 2523
275. A. Okello, J. Koivunen, P. Edison, H.A. Archer, F.E. Turkheimer, and K. Någren et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study Neurology 73 2009 754 760
276. A. Nordberg, S.F. Carter, J. Rinne, A. Drzezga, D.J. Brooks, and R. Vandenberghe et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease Eur J Nucl Med Mol Imaging 40 2013 104 114
277. R.E. Amariglio, J.A. Becker, J. Carmasin, L.P. Wadsworth, N. Lorius, and C. Sullivan et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals Neuropsychologia 50 2012 2880 2886
278. E.M. Reiman, K. Chen, X. Liu, D. Bandy, M. Yu, and W. Lee et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease Proc Natl Acad Sci USA 106 2009 6820 6825
279. M.A. Mintun, G.N. Larossa, Y.I. Sheline, C.S. Dence, S.Y. Lee, and R.H. Mach et al. [11 C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease Neurology 67 2006 446 452 (Pubitemid 44214969)
280. T. Hedden, K.R. Van Dijk, J.A. Becker, A. Mehta, R.A. Sperling, and K.A. Johnson et al. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden J Neurosci 29 2009 12686 12694
281. D.J. Selkoe Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior Behav Brain Res 192 2008 106 113
282. S. Förster, T. Grimmer, I. Miederer, G. Henriksen, B.H. Yousefi, and P. Graner et al. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay Biol Psychiatry 71 2012 792 797
283. J.O. Rinne, D.J. Brooks, M.N. Rossor, N.C. Fox, R. Bullock, and W.E. Klunk et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 9 2010 363 372
284. K.A. Johnson, S. Minoshima, N.I. Bohnen, K.J. Donohoe, N.L. Foster, and P. Herscovitch et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association J Nucl Med 54 2013 476 490
285. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, R.C. Petersen, M.W. Weiner, and P.S. Aisen et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers Lancet Neurol 12 2013 207 216
286. D.S. Knopman, C.R. Jack Jr., H.J. Wiste, S.D. Weigand, P. Vemuri, and V.J. Lowe Brain injury biomarkers are not dependent on β-amyloid in normal elderly Ann Neurol 2012 10.1002/ana.23816
287. Y.I. Sheline, J.C. Morris, A.Z. Snyder, J.L. Price, Z. Yan, and G. D'Angelo et al. APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42 J Neurosci 30 2010 17035 17040
288. N. Okamura, S. Furumoto, R. Harada, T. Tago, T. Yoshikawa, and M.
289. C. Micanovic, and S. Pal The diagnostic utility of EEG in early-onset dementia: a systematic review of the literature with narrative analysis J Neural Transm 2013 10.1007/s00702-013-1070-5
290. C.J. Stam Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders J Neurol Sci 289 2010 128 134
291. C. Babiloni, R. Ferri, G. Binetti, A. Cassarino, G. Dal Forno, and M. Ercolani et al. Fronto-parietal coupling of brain rhythms in mild cognitive impairment: a multicentric EEG study Brain Res Bull 69 2006 63 73 (Pubitemid 43185345)
292. S. Poil, W. De Haan, W.M. van der Flier, H.D. Mansvelder, P. Scheltens, and K. Linkenkaer-Hansen Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage Front Aging Neurosci 5 2013 58
293. C. Luckhaus, B. Grass-Kapanke, I. Blaeser, R. Ihl, T. Supprian, and G. Winterer et al. Quantitative EEG in progressing vs. stable mild cognitive impairment (MCI): results of a 1-year follow-up study Int J Geriatr Psychiatry 23 2008 1148 1155
294. M. Grunwald, F. Busse, A. Hensel, F. Kruggel, S. Riedel-Heller, and H. Wolf et al. Correlation between cortical theta activity and hippocampal volumes in health, mild cognitive impairment, and mild dementia J Clin Neurophysiol 18 2001 178 184 (Pubitemid 32549914)
295. V. Jelic, S.E. Johansson, O. Almkvist, M. Shigeta, P. Julin, and A. Nordberg et al. Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease Neurobiol Aging 21 2000 533 540 (Pubitemid 30621491)
296. J. Dauwels, F. Vialatte, T. Musha, and A. Cichocki A comparative study of synchrony measures for the early diagnosis of Alzheimer's disease based on EEG Neuroimage 49 2010 668 693
297. C.J. Stam, T. Montez, B.F. Jones, S.A. Rombouts, Y. van der Made, and Y.A. Pijnenburg et al. Disturbed fluctuations of resting state EEG synchronization in Alzheimer's disease Clin Neurophysiol 116 2005 708 715 (Pubitemid 40249838)
298. V. Drago, C. Babiloni, D. Bartrés-Faz, A. Caroli, B. Bosch, and T. Hensch et al. Disease tracking markers for Alzheimer's disease at the prodromal (MCI) stage J Alzheimers Dis 26 2011 159 199
299. W.J. Jagust, S.M. Landau, L.M. Shaw, J.Q. Trojanowski, R.A. Koeppe, and E.M. Reiman et al. Relationships between biomarkers in aging and dementia Neurology 73 2009 1193 1199
300. G.D. Rabinovici, and W.J. Jagust Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo Behav Neurol 21 2009 117 128
301. B. Dubois, G. Picard, and M. Sarazin Early detection of Alzheimer's disease: new diagnostic criteria Dialogues Clin Neurosci 11 2009 135 139
302. C.E. Jackson, and P.J. Snyder Electroencephalography and event-related potentials as biomarkers of mild cognitive impairment and mild Alzheimer's disease Alzheimers Dement 4 2008 S137 S143
303. V. Papaliagkas, V. Kimiskidis, M. Tsolaki, and G. Anogianakis Usefulness of event-related potentials in the assessment of mild cognitive impairment BMC Neurosci 9 2008 107
304. J.M. Olichney, J.R. Taylor, J. Gatherwright, D.P. Salmon, A.J. Bressler, and M. Kutas et al. Patients with MCI and N400 or P600 abnormalities are at very high risk for conversion to dementia Neurology 70 2008 1763 1770 (Pubitemid 351653959)
305. A. Vincent Methods for improving the signal-to-noise ratio of endogenous-evoked potentials Integr Physiol Behav Sci 27 1992 54 65
306. B.C. Dickerson, and R.A. Sperling Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging Behav Neurol 21 2009 63 75
307. R. Nisticò, M. Pignatelli, S. Piccinin, N.B. Mercuri, and G. Collingridge Targeting synaptic dysfunction in Alzheimer's disease therapy Mol Neurobiol 46 2012 572 587
308. N. Kozauer, and R. Katz Regulatory innovation and drug development for early-stage Alzheimer's disease N Engl J Med 368 2013 1169 1171
309. H. Hampel, and M.C. Carrillo Alzheimer's disease - modernizing concept, biological diagnosis and therapy 1st ed. Advances in biological psychiatry vol. 28 2012 Karger Basel
310. A.H. Noel-Storr, L. Flicker, C.W. Ritchie, G.H. Nguyen, T. Gupta, and P. Wood et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia Alzheimers Dement 9 2013 e96 e105
311. A. Cortes-Blanco, C. Prieto-Yerro, R. Martinez-Lazaro, J. Zamora, A. Jiménez-Huete, and M. Haberkamp Florbetapir (18F) for brain amyloid imaging - abstract F3-04-01 Alzheimers Dement 8 2012 425 426
312. R. Sperling, and K. Johnson Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria Continuum (Minneapolis, Minn) 19 2013 325 338
313. E. Richard, B.A. Schmand, P. Eikelenboom, W.A. Van Gool, and Alzheimer's disease Neuroimaging Initiative MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study Br Med J 2013 10.1136/bmjopen-2012- 002541 pii: e002541
314. D. Prvulovic, and H. Hampel Ethical considerations of biomarker use in neurodegenerative diseases - a case study of Alzheimer's disease Prog Neurobiol 95 2011 517 519
315. H. Hampel, G. Wilcock, S. Andrieu, P. Aisen, K. Blennow, and K. Broich et al. Biomarkers for Alzheimer's disease therapeutic trials Prog Neurobiol 95 2011 579 593
316. J.X. Lu, W. Qiang, W.M. Yau, C.D. Schwieters, S.C. Meredith, and R. Tycko Molecular structure of β-amyloid fibrils in Alzheimer's disease brain tissue Cell 154 2013 1257 1268
317. A. Aguzzi, and A.D. Gitler A template for new drugs against Alzheimer's disease Cell 154 2013 1182 1184
318. H. Zetterberg, D.H. Smith, and K. Blennow Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood Nat Rev Neurol 9 2013 201 210
319. N. Andreasen, and H. Zetterberg Amyloid-related biomarkers for Alzheimer's disease Curr Med Chem 15 2008 766 771 (Pubitemid 351516792)
320. E.M. Reiman, J.B. Langbaum, A.S. Fleisher, R.J. Caselli, K. Chen, and N. Ayutyanont et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments J Alzheimers Dis 26 2011 321 329
321. R. Sperling, M. Donohue, and P. Aisen The A4 trial: anti-amyloid treatment of asymptomatic Alzheimer's disease. Abstract F3-04-01 Alzheimers Dement 8 2012 425 426
322. C.C. Rowe, K.A. Ellis, M. Rimajova, P. Bourgeat, K.E. Pike, and G. Jones et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283
323. A. Solomon, M. Kivipelto, and H. Soininen Prevention of Alzheimer's disease: moving backward through the lifespan J Alzheimers Dis 33 2013 S465 S469
324. B. Vellas, P.S. Aisen, C. Sampaio, M. Carrillo, P. Scheltens, and B. Scherrer et al. Prevention trials in Alzheimer's disease: an EU-US task force report Prog Neurobiol. 95 2011 594 600
325. F. Noorbakhsh, C.M. Overall, and C. Power Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology Trends Neurosci 32 2009 88 100
326. J.A. Miller, M.C. Oldham, and D.H. Geschwind A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging J Neurosci 28 2008 1410 1420 (Pubitemid 351231536)
327. P. Hallock, and M.A. Thomas Integrating the Alzheimer's disease proteome and transcriptome: a comprehensive network model of a complex disease OMICS 16 2012 37 49